Introduction
It has been well established that all successful tumors must undergo neovascularization, or angiogenesis, in order to acquire nutrients for continued growth and metastatic spread (Folkman, 1995) . Vascular endothelial growth factor (VEGF) is one of the most important of all known inducers of angiogenesis (Grunstein et al., 1999; Millauer et al., 1994; Plate et al., 1992; Shweiki et al., 1992) . Induction of VEGF and tumor angiogenesis can develop as a result of environmental conditions, notably hypoxia (Mukhopadhyay et al., 1995b; Shweiki et al., 1992) , or genetic alterations (Jiang et al., 2000; Pages et al., 2000; Rak et al., 1995 Rak et al., , 2000 , including activation of oncogenic tyrosine kinases (Dankbar et al., 2000; Ellis et al., 1998; Mukhopadhyay et al., 1995a; Petit et al., 1997; Wiener et al., 1999) . Constitutive activation of tyrosine kinases is highly prevalent in a wide range of cancers and their role as important VEGF inducers has been well established. For example, abnormal activation of EGFR and Src signaling pathways that induce VEGF expression Mukhopadhyay et al., 1995a; Petit et al., 1997; Wiener et al., 1999) has been demonstrated in breast cancer (Garcia et al., 1997 (Garcia et al., , 2001 Khazaie et al., 1993; Luttrell et al., 1988 Luttrell et al., , 1994 Muthuswamy and Muller, 1995) , while activation of IL-6 receptor, which signals through another tyrosine kinase signaling pathway, is responsible for myeloma VEGF expression and vascularization (Dankbar et al., 2000) .
Although tyrosine kinases signal through multiple pathways, Stat3 is a point of convergence for many of these Bromberg and Darnell, 2000; Catlett-Falcone et al., 1999a) . Accumulating evidence is de®ning a critical role for Stat3 in oncogenesis Bromberg and Darnell, 2000; Bromberg et al., 1999; Catlett-Falcone et al., 1999a,b; Grandis et al., 2000) . It has been shown that constitutive activation of Stat3 signaling contri-butes to oncogenesis by preventing programmed cell death and enhancing cell proliferation Catlett-Falcone et al., 1999b; Grandis et al., 1998 Grandis et al., , 2000 . Stat3 is constitutively activated at high frequency in a wide range of cancers, including various blood malignancies, breast cancer, head and neck cancer, prostate cancer and melanoma Bromberg and Darnell, 2000; Catlett-Falcone et al., 1999a,b; Garcia et al., 2001; Grandis et al., 1998 Grandis et al., , 2000 Ni et al., 2000; Niu et al., 1999) Stat3 DNAbinding activity determined by EMSA using nuclear extracts prepared from human breast cancer, head and neck carcinoma, and melanoma cell lines. EGFR-expressing NIH3T3 ®broblasts were stimulated with EGF and used here as markers for activated Stat3 and Stat1 dimers bound to labeled hSIE probe. Lower panel: Western blot analysis of lysates from the same cells probed with VEGF or b-actin antibodies. The relative levels of Stat3-DNA binding activity and VEGF protein expression were quanti®ed by ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). The overall correlation coecient between VEGF expression and Stat3 activity in the three groups of tumor cell lines is 0.936 with a P-value of 50.001. (b) Supershift analysis using Stat1 and Stat3 speci®c antibodies incubated with nuclear extracts from the indicated cancer cell lines con®rmed that Stat3, but not Stat1, was activated. Previous studies demonstrated activation of Stat3, but not Stat1, in MDA-MB-453 and SK-BR-3 cell lines (Garcia et al., 1997) 
Results
Stat3 activity is associated with VEGF up-regulation in diverse human cancer cell lines
To evaluate if constitutively-activated Stat3 may contribute to VEGF up-regulation in cancer, we ®rst assessed VEGF expression and Stat3 activity in 10 human cancer cell lines, which span three dierent types of cancer (Figure 1 ). EGFR and Src signaling pathways, both of which can induce VEGF expression Mukhopadhyay et al., 1995a; Petit et al., 1997; Wiener et al., 1999) , are known to contribute to Stat3 activation in breast cancers (Garcia et al., 1997 (Garcia et al., , 2001 ). In addition, EGFR signaling has been found to activate Stat3 in head and neck carcinoma (Grandis et al., 1998) . As shown in Figure 1a , the expression of VEGF correlated with elevated Stat3 DNA-binding activity in both breast carcinoma and head and neck cancer cell lines. While the oncogenic events responsible for melanoma VEGF up-regulation and Stat3 activity remain to be de®ned, the expression of VEGF also paralleled elevated Stat3 DNA-binding activity in these cells. Supershift experiments with Stat3-speci®c antibodies demonstrate that Stat3 protein is the predominant STAT family member activated in every case (Figure 1b) . Because VEGF expression correlates with Stat3 activity in all of the cancer cell lines examined, constitutive activation of Stat3, which occurs at high frequency in numerous diverse cancers, may be an important inducer of VEGF in cancer angiogenesis.
A constitutively-activated Stat3 mutant induces VEGF expression and stimulates tumor angiogenesis
To directly test the hypothesis that constitutivelyactivated Stat3 has a causal role in VEGF induction in tumor cells, we determined whether persistent Stat3 signaling by itself could up-regulate VEGF expression. Stable expression of Stat3C, an oncogenic mutant form of Stat3 that is constitutively activated without tyrosine phosphorylation (Bromberg et al., 1999) , in NIH3T3 ®broblasts led to increased Stat3 DNA-binding activity and enhanced expression of VEGF (Figure 2a ). Of the four Stat3C-transfected NIH3T3 clones that survived G418 selection, only one (Stat3C-5) did not contain elevated Stat3 DNA-binding activity. Lack of increased Stat3 activity in these cells correlated with the absence of enhanced VEGF expression when compared to that of wild-type NIH3T3 cells. B16 murine melanoma cells display relatively low levels of constitutive Stat3 activation (Niu et al., 1999) , and enforced expression of Stat3C up-regulated the expression of VEGF (Figure 2b ). When these Stat3C-transfected B16 tumor cells were mixed with Matrigel and implanted in vivo, a robust increase in vascularization was observed ( Figure  3a ). This increased angiogenesis was con®rmed by higher hemoglobin content ( Figure 3b ). These ®ndings, 
Stat3 up-regulates VEGF expression through the VEGF gene promoter
Our results thus far show that Stat3 activity stimulates VEGF expression and tumor angiogenesis. We next investigated if Stat3 could regulate the VEGF promoter directly. By searching for potential STATbinding sites with the consensus sequences, TT(N 4 )AA and TT(N 5 )AA (Seidel et al., 1995) , six candidate Stat3-binding sites were identi®ed in the 2.4 kb VEGF promoter region. Two sites at positions 7848 and 7630 upstream of the transcription initiation site in the VEGF promoter most closely resembled a previously de®ned Stat3-binding site within the C-reactive protein (CRP) promoter (Turkson et al., 1998; Zhang et al., 1996) . The site at 7848 has a one-base mismatch relative to the CRP Stat3-binding site, while the site at 7630 has two-base mismatches ( Figure 4a ). Because an individual natural STAT-binding site can have weak binding anity (Xu et al., 1996) , we tested if candidate Stat3-binding sites in the VEGF promoter could compete for the binding of Stat3 to a high-anity variant of the Stat3-binding site in the c-fos promoter's sis-inducible element (hSIE) (Wagner et al., 1990 ). An oligonucleotide containing the putative VEGF Stat3-binding site at 7848 competed eectively with labeled hSIE probe for Stat3 binding (Figure 4b ). In contrast, the putative VEGF Stat3-binding site at 7630, which has two mismatch bases instead of one, could not compete for the binding of Stat3 to hSIE (data not shown). The competition against hSIE using an oligonucleotide containing the VEGF Stat3-binding site at 7848 was speci®c, since an irrelevant oligonucleotide (FIRE) (Turkson et al., 1998) and a mutated form of the 7848 Stat3-binding oligonucleotide (Figure 4a , line 3) failed to compete with hSIE for Stat3 binding (Figure 4b ). To determine if Stat3 protein could directly bind to the Stat3-binding site in the VEGF promoter in vivo, chromatin immunoprecipitation (ChIP) assays were performed (Wells et al., 2000) . This technique allows for the detection of speci®c genomic DNA sequences that are associated with a particular transcription factor in intact cells. As shown in Figure 4c , an association of Stat3 with the VEGF promoter in vivo in v-Src transformed NIH3T3 cells was detected. Immunoprecipitation with a Stat3 antibody followed by PCR using oligonucleotide primers that amplify a 130-bp region spanning the Stat3-binding site at 7848 (c) Chromatin immunoprecipitation (ChIP) assay was performed using either a Stat3-speci®c antibody, an irrelevant antibody (antiRho), or no antibody. PCR primers were designed to yield a 130-bp product, which includes the Stat3-binding site (7848) of the VEGF promoter. As a negative control, PCR reactions using primers for the mouse albumin gene previously described (Wells et al., 2000) were included in these experiments. Input lane represents 0.02% of total chromatin used in ChIP assays. We next tested if mutating the Stat3-binding site in the VEGF promoter would result in loss of Stat3C-induced VEGF promoter activity. The same mutations at the 7848 site shown in Figure 4a were introduced into the VEGF promoter linked to a luciferase reporter construct, pGL3VEGF (Akagi et al., 1998) . Cotransfection of Stat3C expression vector and wild-type pGL3VEGF into B16 cells stimulated VEGF promoter activity (Figure 4d ). In contrast, when the Stat3-binding site at 7848 was mutated in pGL3VEGF, Stat3C-induced VEGF promoter activity was abrogated ( Figure 4d ). Taken together, these data provide evidence that Stat3 induces VEGF expression directly through the VEGF promoter.
Blocking Stat3 in tumor cells down-regulates VEGF expression
To determine if Stat3 is a potential target for antiangiogenic therapy, we assessed whether blocking Stat3 signaling in tumor cells down-regulates VEGF expression. B16 tumor cells were transiently transfected with either an expression vector encoding a dominantnegative variant of Stat3 protein, designated Stat3b (Caldenhoven et al., 1996; Turkson et al., 1998) , or Stat3 antisense oligonucleotide. As shown in Figure 5a , inhibition of constitutive Stat3 signaling by either approach in B16 tumor cells down-regulates expression of the endogeneous VEGF gene. To con®rm that blocking Stat3 signaling represses transcriptional activity of the VEGF promoter under these conditions, B16 cells were transfected with Stat3b expression vector and a luciferase reporter construct based on the VEGF promoter (Akagi et al., 1998) . In the absence of Stat3b expression, VEGF promoter activity was readily detectable in B16 tumor cells as indicated by expression levels of luciferase. Co-transfection of Stat3b vector, but not the control empty vector, decreased transcriptional activity of the VEGF promoter by 2 ± 3-fold ( Figure 5c ). This inhibitory eect on transcriptional activity of the VEGF promoter was also observed in B16 tumor cells transfected with Stat3 antisense oligonucleotide (Figure 5c ). The murine mammary tumor cell line, SCK-1, also displays constitutively-activated Stat3 (data not shown). Transcriptional down-regulation of VEGF expression as a consequence of disruption of Stat3 signaling was veri®ed in SCK-1 cells (Figure 5b,d ). These results demonstrate that interrupting constitutive Stat3 signaling in tumor cells down-regulates VEGF expression.
Stat3 is obligatory for Src-induced VEGF up-regulation
Abnormal activation of the Src tyrosine kinase is prevalent in diverse cancers and its role in VEGF induction and tumor angiogenesis has been well documented Mukhopadhyay et al., 1995a; Wiener et al., 1999) . Src has also been shown to be obligatory for hypoxia-induced VEGF expression (Mukhopadhyay et al., 1995b) , further demonstrating a pivotal role of Src in tumor angiogenesis. While Src tyrosine kinase is known to activate multiple signaling pathways, like many oncogenic tyrosine kinases Src is upstream of Stat3 (Bromberg et al., 1998; Turkson et al., 1998; Yu et al., 1995) . To assess whether Stat3 is necessary for VEGF up-regulation by v-Src, we determined if blocking Stat3 signaling could inhibit VEGF expression induced by Src tyrosine kinase activity. NIH3T3 ®broblasts stably transformed by the v-Src oncoprotein (Turkson et al., 1998) were transiently transfected with a Stat3b expression vector. Enforced Stat3b expression was accompanied by a reduction of VEGF expression in v-Src-NIH3T3 ®broblasts (Figure 6a ). Stat3 antisense oligonucleotide or control mismatch oligonucleotide was also transfected into v-Src-NIH3T3 cells. A reduction of endogenous Stat3 protein levels as a result of Stat3 antisense oligonucleotide transfer caused inhibition of VEGF expression (Figure 6a ). Furthermore, transcriptional activity of the VEGF promoter (Akagi et al., 1998) was diminished by the dominant-negative Stat3b protein, as shown by luciferase reporter gene expression assays (Figure 6b ). We further determined if Stat3 binding to the VEGF promoter is required for Srcinduced VEGF expression. As shown in Figure 6c , sitespeci®c mutations of the Stat3-binding site at position 7848 within the VEGF promoter abrogated Srcinduced VEGF promoter activity. Taken together, these results demonstrate that Src-induced VEGF upregulation requires Stat3-mediated activation of VEGF promoter.
Discussion
Both VEGF over-expression and constitutive activity of Stat3 occur at high frequency in diverse human tumors. While previous work has shown that Stat3 signaling is required for gp130-induced VEGF expression in cardiac myocytes (Funamoto et al., 2000) , whether constitutive Stat3 activation is sucient to induce VEGF up-regulation and thus contribute to tumor angiogenesis has not been addressed before. Furthermore, the signaling pathway downstream of Stat3 leading to VEGF induction has not been de®ned. Our results show that constitutively-activated Stat3 alone is capable of activating VEGF expression and stimulating tumor angiogenesis. Moreover, Stat3-induced VEGF up-regulation requires the Stat3-binding site at position 7848 in the VEGF promoter and Stat3 protein binds to the VEGF promoter region containing this site in vivo, providing evidence that VEGF is a direct target gene of Stat3. Our ®ndings also demonstrate that interrupting Stat3 signaling inhibits VEGF expression, identifying Stat3 as a promising molecular target for tumor anti-angiogenesis therapy.
As Stat3 is downstream of several important angiogenic tyrosine kinases, such as Src and EGFR, our ®ndings suggest that blocking Stat3 may inhibit neovascularization mediated by multiple angiogenic signaling pathways. Consistent with this hypothesis, we show that Src-induced VEGF up-regulation requires Stat3 activation and the identi®ed Stat3-binding site in the VEGF promoter. Because Src activation is necessary for VEGF up-regulation induced by hypoxia, which has a pivotal role in solid tumor angiogenesis (Mukhopadhyay et al., 1995b; Shweiki et al., 1992) , targeting Stat3 in tumors may potentially not only inhibit VEGF expression induced by many oncogenic tyrosine kinases prevalent in cancers, but also block hypoxia-mediated VEGF up-regulation. In addition to tyrosine kinases, other oncogenic signaling pathways that are independent of Stat3 are also known to induce VEGF expression in tumors (Jiang et al., 2000; Pages et al., 2000; Rak et al., 1995 Rak et al., , 2000 . Nevertheless, our ®nding that VEGF expression correlates with Stat3 activity in many tumor cell lines examined supports a critical role of Stat3 in VEGF up-regulation in a variety of cancers.
The important role of VEGF in inducing tumor angiogenesis has been well established (Grunstein et al., 1999; Millauer et al., 1994; Plate et al., 1992; Shweiki et al., 1992) . However, in addition to an enhanced expression of angiogenic mitogens, such as VEGF, a reduction of angiogenic inhibitors has also been observed during oncogenic progression from normal to cancerous cells (Volpert et al., 1997) . Our recent studies indicate that disrupting Stat3 signaling in tumor cells activates the expression of IP-10 and IFN-b (L Burdelya et al., manuscript in preparation). Because both IP-10 and IFN-b are inhibitors of angiogenesis (Coughlin et al., 1998; Dong et al., 1999) , constitutive activation of Stat3 may also stimulate tumor angiogenesis by down-regulating the expression of angiostatic mediators during malignant progression.
Previous studies have demonstrated that activation of Stat3 by oncogenic tyrosine kinases regulates the expression of genes that are essential for cell growth and survival Bromberg et al., 1999; Catlett-Falcone et al., 1999b; Grandis et al., 2000; Sinibaldi et al., 2000) . Our present ®ndings that constitutive Stat3 activation directly promotes VEGF expression and stimulates tumor angiogenesis indicate a far broader role of Stat3 in cancer pathogenesis than previously anticipated. Thus, constitutive Stat3 activation confers multiple advantages on tumor cells that are essential for successful malignant progression. Because Stat3 represents a point of convergence for many oncogenic as well as angiogenic events, Stat3 is a promising molecular target for powerful intervention in cancer therapy .
Materials and methods

Cell lines and mice
NIH3T3 ®broblasts and v-Src-transformed NIH3T3 cells were grown in DMEM supplemented with 5% calf serum. B16 melanoma and SCK mammary carcinoma cell lines were grown in RPMI medium supplemented with 10% fetal bovine serum (FBS). Human cancer cell lines were obtained from ATCC and grown in DMEM supplemented with 10% FBS. Female, 6 ± 8 weeks old, C57BL/6 mice were purchased from the National Cancer Institute (Bethesda, MD, USA) and used for in vivo tumor angiogenesis assays. Mice were housed in American Association for Accreditation of Laboratory Animal Care-approved, speci®c pathogen-and viral antibody-free facility located at the H. Lee Mott Cancer Center and Research Institute.
Transfection v-Src-transformed NIH3T3 ®broblasts (Turkson et al., 1998) , B16 and SCK tumor cells (Coughlin et al., 1998; Niu et al., 1999) were seeded 18 ± 24 h before transfection with expression plasmids or oligonucleotides using Lipofectamine (Life Technologies). For plasmid transfection, 1 mg of either pIRES-EGFP or pIRES-Stat3b was used (Catlett-Falcone et al., 1999b) . The sequence for Stat3 antisense oligonucleotide synthesized using phosphorothioate chemistry is 5'-AAAAAGTGCCCAGATTGCCC-3'. The sequence for control oligonucleotide is identical to the antisense oligonucleotide except for three mismatched bases (italics), 5'-AAAAAGAGGCCTGATTGCCC-3'. Transfection of Stat3C expression vector (Bromberg et al., 1999) into NIH3T3 ®broblasts and B16 tumor cells was carried out using calcium phosphate precipitation, followed by selection in medium supplemented with 1 mg/ml G418.
Site-specific mutagenesis
The human VEGF promoter reporter construct (pGL3VEGF) consists of a 2.4 kb genomic DNA fragment containing the 5' region of the VEGF gene upstream of the transcription initiation site cloned into the pGL3 vector (Akagi et al., 1998) . Potential Stat3-binding sites in the VEGF promoter were determined by searching the 2.4 kb VEGF gene 5' region for consensus STAT-binding sites, TT(N 4 )AA and TT(N 5 )AA (Seidel et al., 1995) using sequence analysis software by DNAStar. Two sites at positions 7848 and 7630 upstream of the transcription initiation site were selected from this subset that closely resembled a previously-de®ned Stat3-binding site within the CRP promoter (Zhang et al., 1996) . The putative Stat3-binding site at 7848 in the pGL3VEGF plasmid was speci®cally mutated (from 5'-TTCCCAAA-3' to 5'-gcgtCAAA-3') using the unique site elimination method (Deng and Nickolo, 1992) and con®rmed by sequencing.
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Western blot analysis and electrophoretic mobility shift assays (EMSA)
Equal amounts of total cellular proteins were separated by SDS-polyacrylamide gel electrophoresis followed by immunoblotting with anti-Stat3 (K-15, Santa Cruz Biotechnology), anti-VEGF (Neomarkers) or anti-b-actin (Sigma) antibodies, as described (Turkson et al., 1998) . EMSA and competition assays were performed as previously described (Turkson et al., 1998) . The oligonucleotides containing the putative Stat3-binding sites in the VEGF promoter and their derivatives used in EMSA for competing with hSIE probe are as follows: (7848 
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed essentially as previously described (Wells et al., 2000) . Solubilized chromatin was prepared from a total of 3610 7 asynchronously growing vSrc transformed NIH3T3 cells. The chromatin solution was diluted 10-fold with ChIP Dilution Buer (0.01% SDS; 1.1% Triton X-100; 1.2 mM EDTA; 16.7 mM Tris-HCl, pH 8.1; 167 mM NaCl), and precleared with Protein A beads blocked with 1% salmon sperm DNA and 1% BSA. The precleared chromatin solution was divided and utilized in immunoprecipitation assays with either an anti-Stat3 rabbit polyclonal antibody (sc-482, Santa Cruz Biotechnology) or an antiRhoA rabbit polyclonal antibody (sc-179, Santa Cruz Biotechnology). The immunoprecipitates were then pelleted, washed, and the antibody/protein/DNA complex was eluted o the beads by resuspending the pellets in 50 mM NaHCO 3 and 1% SDS for 30 min. Crosslinking was reversed and protein and RNA were removed by adding 10 mg Proteinase K and 10 mg RNase A, followed by incubation at 428C for 3 h. Puri®ed DNA was subjected to PCR with primers speci®c for a 130-bp region (7913 to 7783) spanning the Stat3-binding site (7848) in the VEGF promoter. The sequences of the PCR primers used are as follows: VEGF forward(+): 5'-CTGGCCTGCAGACATCAAAGTGAG-3', and VEGF reverse(7): 5'-CTTCCCGTTCTCAGCTCCA-CAAAC-3'. PCR was run for 38 cycles (948C for 30 s, 588C for 30 s, 728C for 1 min), and ®nal products were resolved on a 2.5% agarose gel containing ethidium bromide.
Luciferase assays
Transfections of pGL3VEGF reporter construct in combination with various vectors for luciferase assays were carried out using Lipofectamine reagent according to the manufacturer's protocol (Gibco). Brie¯y, transfections contained a total of 1 mg of DNA, including 0.1 mg of the indicated luciferase reporter construct, 10 ng b-galactosidase expression vector (internal control), and 0.9 mg of v-Src or Stat3C, or Stat3b expression vectors, or control empty vectors. In experiments where antisense oligonucleotides were used, 300 nM of either Stat3 antisense oligonucleotide or a mismatched oligonucleotide was added to cells. Cytosolic fractions were prepared at 48 h post-transfection (Turkson et al., 1998) . Samples were analysed with a luminometer and normalized to b-galactosidase activity by colorimetric assay at A 570 as an internal control for transfection eciency.
Matrigel assays
Matrigel assays were performed as described previously (Coughlin et al., 1998) . Brie¯y, 2610 5 B16 tumor cells stably transfected with either pcDNA3 or pStat3C were resuspended in 100 ml PBS and mixed with 0.5 ml of Matrigel (Collaborative Biomedical Products) on ice, followed by injection subcutaneously into the abdominal midline of C57BL mice. Matrigel plugs were harvested on day 5 for photography or on day 7 for hemoglobin assays. Hemoglobin quanti®cation was carried out by the Drabkin method (Passaniti et al., 1992) . Brie¯y, after dissecting away all the surrounding tissue, Matrigel pellets were melted at 48C and assayed for hemoglobin content (Drabkin's reagent kit, Sigma).
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